CYP3A4 and cystic fibrosis: Many commonly co-administered drugs in CF patients can inhibit CYP3A (e.g., azole antifungals) or are metabolized by CYP3A (e.g., antibiotics, steroids) [16], suggesting their potential influence on pharmacokinetic variability in caftor exposure.